R&D

R&D

Pipeline
Pipeline
Clinical Trial Information
Clinical Trial Information

R&D News

View more
  • September 18, 2026 Tanabe Pharma announces FDA Acceptance of New Drug Application for dersimelagon, a potential first-in-class oral therapy for EPP and XLP and the Completion of the Transfer of dersimelagon business rights pdf （451KB）
  • July 31, 2026 Pipeline ― State of New Product Development
  • June 24, 2026 Commencement of a Prospective Observational Study on the Long-Term Efficacy and Safety of Uplizna for IgG4-Related Disease pdf （683KB）
  • May 13, 2026 Pipeline ― State of New Product Development
  • March 31, 2026 Notice of Dissolution of Joint Venture relationship with respect to BIKEN Co., Ltd. pdf （113KB）
  1. Tanabe Pharma Corporation
  2. R&D
  3. TOP
  • header-content
  • header-content

  • CLOSE
  • MENU

Site Search

If you agree to the use of cookies, please click the "Agree" button.
If you do not agree, please do not use this site. For details, please refer to the following page.

Privacy Policy

Agree

URL
 

田辺ファーマ株式会社のサイトを離れます。よろしいですか？
（別ウィンドウが開きます）

You are leaving the Tanabe Pharma Corporation’s website.
(A new window will be opened.)

はい / O.K.
いいえ / Cancel
  • footer-content